VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.

Animals Carcinoma, Renal Cell / pathology Cell Line, Tumor Disease Models, Animal Gene Expression Profiling Humans Mice Neoplasm Transplantation Transplantation, Heterologous Vascular Endothelial Growth Factor C / metabolism
CRISPR/Cas9 VEGFC angiogenesis lymphangiogenesis metastasis renal cell carcinoma sunitinib

Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2019
Historique:
received: 11 06 2018
accepted: 30 07 2018
entrez: 28 2 2019
pubmed: 28 2 2019
medline: 18 12 2019
Statut: epublish

Résumé

Hypoxic zones are common features of metastatic tumors. Due to inactivation of the von Hippel-Lindau gene (

Identifiants

DOI: 10.7150/thno.27794 PMID: 30809300 PMC: PMC6376471
pubmed: 30809300
doi: 10.7150/thno.27794
pii: thnov09p0661
pmc: PMC6376471
doi:

Substances chimiques

VEGFC protein, human 0
Vascular Endothelial Growth Factor C 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

661-675

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no conflict of interest exists.

Références

Nature. 2016 Nov 3;539(7627):107-111
pubmed: 27595393
Clin Cancer Res. 2005 Feb 15;11(4):1434-40
pubmed: 15746043
Oncotarget. 2017 Jan 17;8(3):5603-5618
pubmed: 27901498
Dev Biol. 2007 Feb 15;302(2):602-16
pubmed: 17098221
Cancer Res. 2013 Jul 15;73(14):4579-4590
pubmed: 23689123
Oncogene. 1997 May 22;14(20):2475-83
pubmed: 9188862
Blood. 2007 Feb 1;109(3):1010-7
pubmed: 17032920
Front Physiol. 2014 Mar 05;5:75
pubmed: 24634660
J Clin Invest. 2014 Mar;124(3):922-8
pubmed: 24590277
Eur Urol. 2016 Apr;69(4):646-657
pubmed: 26298207
Cell Death Differ. 2008 Sep;15(9):1472-80
pubmed: 18511933
Lancet Oncol. 2013 May;14(6):552-62
pubmed: 23598172
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Oncol Rep. 2008 Oct;20(4):721-5
pubmed: 18813809
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cancer Cell. 2009 Mar 3;15(3):232-9
pubmed: 19249681
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Cancer Res. 2017 Mar 1;77(5):1212-1226
pubmed: 28087600
Oncogene. 2000 Nov 16;19(48):5435-43
pubmed: 11114720
Cancer Sci. 2014 Sep;105(9):1142-51
pubmed: 24981602
Mol Cell Biol. 2009 May;29(10):2570-81
pubmed: 19273585
Lancet Oncol. 2016 Jan;17(1):e4-5
pubmed: 26758760
J Clin Oncol. 2008 Aug 1;26(22):3743-8
pubmed: 18669461
J Natl Cancer Inst. 2012 Jan 18;104(2):93-113
pubmed: 22235142
J Clin Invest. 2012 May;122(5):1895-906
pubmed: 22466647
Angiogenesis. 2014 Apr;17(2):383-93
pubmed: 24154862
Cell Rep. 2013 Feb 21;3(2):277-81
pubmed: 23395639
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Carcinogenesis. 2007 Mar;28(3):529-36
pubmed: 16920734
Am J Pathol. 2017 Aug;187(8):1736-1749
pubmed: 28627412
Br J Cancer. 2007 Oct 22;97(8):1090-8
pubmed: 17912247
PLoS One. 2012;7(4):e35094
pubmed: 22545097
Semin Cancer Biol. 2013 Feb;23(1):18-25
pubmed: 22705278
J Cell Biol. 2012 Sep 3;198(5):815-32
pubmed: 22945933
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
IUBMB Life. 2015 Mar;67(3):145-59
pubmed: 25899846
Oncogenesis. 2017 Jul 3;6(7):e354
pubmed: 28671677
J Cell Physiol. 2008 Dec;217(3):809-18
pubmed: 18720385
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
J Biol Chem. 2010 Jan 29;285(5):3092-102
pubmed: 19920141
Cell Rep. 2012 Mar 29;1(3):191-9
pubmed: 22832193
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Biol Chem. 2005 Sep 2;280(35):31132-40
pubmed: 15994306
Cell Rep. 2014 Jan 16;6(1):155-67
pubmed: 24388748
Br J Cancer. 2017 Sep 26;117(7):947-953
pubmed: 28850564
Cancer Res. 2008 Nov 1;68(21):8667-72
pubmed: 18974107
Eur Urol Focus. 2016 Feb;1(3):284-290
pubmed: 28723401
Nat Immunol. 2004 Jan;5(1):74-80
pubmed: 14634646
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Int J Cancer. 2017 Jan 1;140(1):142-148
pubmed: 27623354
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
Clin Genitourin Cancer. 2017 Feb;15(1):e1-e7
pubmed: 27444986
Oncogene. 2012 Oct 18;31(42):4499-508
pubmed: 22179834
Cancer Sci. 2014 Oct;105(10):1261-71
pubmed: 25154789
Clin Cancer Res. 2015 Feb 15;21(4):916-24
pubmed: 25501128
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Br J Cancer. 2006 Apr 24;94(8):1154-63
pubmed: 16570043
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Iran J Public Health. 2014 Feb;43(2):128-35
pubmed: 26060735
Br J Cancer. 2015 Jun 30;113(1):12-9
pubmed: 26086878

Auteurs

Papa Diogop Ndiaye (PD)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Maeva Dufies (M)

Centre Scientifique de Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000 Monaco, Principality of Monaco.

Sandy Giuliano (S)

Centre Scientifique de Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000 Monaco, Principality of Monaco.

Laetitia Douguet (L)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Renaud Grépin (R)

Centre Scientifique de Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000 Monaco, Principality of Monaco.

Jérôme Durivault (J)

Centre Scientifique de Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000 Monaco, Principality of Monaco.

Philippe Lenormand (P)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Natacha Glisse (N)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Janita Mintcheva (J)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Valérie Vouret-Craviari (V)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Baharia Mograbi (B)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.

Maud Wurmser (M)

Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, Paris, 75014 France; CNRS UMR 8104, Paris, 75014 France, Paris, 75014 France.

Damien Ambrosetti (D)

Nice University Hospital, Central laboratory of Pathology.

Nathalie Rioux-Leclercq (N)

Rennes University, Rennes University Hospital, Department of Pathology, Rennes, France.

Pascal Maire (P)

Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, Paris, 75014 France; CNRS UMR 8104, Paris, 75014 France, Paris, 75014 France.

Gilles Pagès (G)

University of Nice Sophia Antipolis, Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, France.
Centre Scientifique de Monaco, Biomedical Department, 8 Quai Antoine Ier, MC-98000 Monaco, Principality of Monaco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de profil d'expression de gènes › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation hétérologue › VEGFC acts as a double-edged sword in renal...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines angiogéniques › Facteurs de croissance endothéliale vasculaire › Facteur de croissance endothéliale vasculaire de type C › VEGFC acts as a double-edged sword in renal...